Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon May 14, 2024 2:43pm
104 Views
Post# 36039370

RE:RE:HC Wainwright & Co

RE:RE:HC Wainwright & Co
Didn't Wainright also used to have a 15 dollar price target and then lowered it to 6 dollars. What happened to their confidence in the company.
It was not the best CC that the company has had and especially now no mention of the panc phase 3 starting mid year and that has even been removed from the investor presentation and now only an update.
I guess it makes sense as they need a partner to be able to help fund the trial before they can start it so let's hope that negotiations are going on for real and not just playing games in the Black out at the expense of the shareholders.
If they are waiting for an inflection point such as OS and then we get the fda C guidance then it is possible that any phase 3 trial might not be able to start until 2025 which is quite different from MC stating that we would have 2 phase 3 trials going by end of 2023. Nothing like misleading shareholders.
Oh well and so we wait, what the heck, it's only been 7 years since we had mbc phase 3 approval with a spa so this round has gotta be better.
The thing that might change it all is an out of the blue announcement that is either a BO or partnership.
<< Previous
Bullboard Posts
Next >>